

APPLICATION FOR HUMIRA® (adalimumab)

myAbbVie Assist provides free medicine to qualifying patients. We review all applications on a case-by-case basis. Participation in our program is free; we do not collect any fees from people seeking our assistance.

CHECKLIST FOR SUBMITTING AN APPLICATION

☐ IF YOU ARE THE PRESCRIBER, COMPLETE PAGE 2

- o **SECTION 1:** Prescriber Information and Shipping Preference
- o **SECTION 2:** Patient History, Diagnosis
- SECTION 3: Prescription
- SECTION 4: Prescriber Certification and Signature

☐ IF YOU ARE A PATIENT, COMPLETE PAGE 3. PLEASE READ PAGE 4.

- SECTION 5: Patient Information
- SECTION 6: Financial and Medical Information
 - REQUIRED: Please include proof of income for all in household. A copy of your current federal tax return
 is preferred. If you do not file taxes, alternate documents are acceptable such as W-2 form, Social Security
 Statement or Pay Stubs.
- SECTION 7: Insurance Information
 - If you have Insurance, include front and back copies of all prescription insurance cards.
 - To help us determine your eligibility please also include a detailed list of prescription and medical out of pocket expenses for the household. If you have multiple prescriptions, your pharmacy can print you a list.
- SECTION 8: Additional Permission for Program Purposes (Optional)
- SECTION 9: Patient Consent and Signature
 - Carefully read the HIPAA authorization, patient terms of participation and privacy notice in Section 10 on Page 4.
 - Provide your consent for eligibility determination by checking the box in Section 9
 - Confirm your understanding of our privacy policy by providing your signature and date in Section 9.

Please keep a copy for your records.

Please do not staple documents together when mailing.

FAX OR MAIL THE COMPLETED APPLICATION AND DOCUMENTATION TO THE FOLLOWING

myAbbVie Assist D-617927, AP5 NE 1 N. Waukegan Rd. North Chicago, IL 60064 Phone: 1-800-222-6885 **Fax: 1-866-250-2803**

Upon review of a completed application, we will notify the prescriber and patient about eligibility. If approved, we will ship the medication to the patient's home unless otherwise indicated on the application. Prior to each subsequent shipment, we will call the patient or prescriber to schedule the next delivery.

Please contact us at 1-800-222-6885 Monday through Friday for additional assistance.

©2021 AbbVie H-APP1-21C-1 March 2021

PHONE: 1-800-222-6885 FAX: 1-866-250-2803



APPLICATION FOR HUMIRA® (adalimumab)

1 PRESCRIBE	R INFORMATION • SHIPPI	NG PREFERENCE					
Prescriber Nam	☐ MD ☐	☐ MD ☐ DO ☐ Other: ☐ Rheum ☐ Dern		m ☐ Gastro ☐ Other	r:		
Office Name:			Office Contact N	Name:			
Address: City/State/Zip:							
NPI or SLN:	Phone:			Fax:			
Collaborating MD Nar	ne and NPI (if applicable) Name:			NPI:			
	prefer shipping to the Prescrib						
	ation on how AbbVie processes	your personal informat	ion, please vis	it www.abbvie.com/privacy.html.			
2 PAHENI M	EDICAL HISTORY			Patient	☐ Cellpl	hone	
Patient's Name	:	DC	B:	Phone:	•	Home	
☐ No known a	allergies	ease list):			Patient Weight*		
☐ No other m		ations (Please list):			(if under age 18):		
☐ RHEUMATOID ART	HRITIS PSORIATIC AF	RTHRITIS		QUE PSORIASIS ANKYLOSING SPONDYLITIS		YLITIS	
CROHN'S DISEASE							
☐ PEDIATRIC CROHN		CERATIVE COLITIS*		IDIOPATHIC ARTHRITIS (JIA)*	OTHER:		
3 RX: MUST E	SE COMPLETED BY A LICE	NSED PRESCRIBE	R AND FAXI	ED DIRECTLY FROM PRESC	RIBER'S OFFICE		
	NG THERAPY OPTIONS		QTY	CHOOSE ONE DIRECTION FO	OR USE		
	S / ADOLESCENT HS (Age 12 & d	= : :					
_	.8 mL (1) & 40 mg/0.4 mL (2) CIT		3 PEN KIT 4 SYRINGES	☐ Inject 80 mg SQ on Day 1, 40) mg on Day 8, and	No refills	
	.4 mL CITRATE FREE SYRINGE	<u> </u>	4 SYRINGES	40 mg every other week			
	ULCERATIVE COLITIS / HS .8 mL CITRATE FREE PEN		0 DEN 147	☐ Inject 160mg SQ on Day 1 and 80 mg on Day 15			
•	4 mL CITRATE FREE SYRINGE		3 PEN KIT	☐ Inject 80mg SQ on Day 1, Da	ıy 2, and Day 15	No refills	
			OUTHINGEO				
PEDIATRIC CROHN'S DISEASE (Weight: 17kg (37 lbs) to < 40kg (88 lbs))) ☐ HUMIRA 80 mg/0.8 mL & 40 mg/0.4 mL CITRATE FREE SYRINGE 2 SYRINGE KIT			2 SYRINGE KIT	☐ Inject 80 mg SQ on Day 1 an	d 40 mg on Day 15	No refills	
PEDIATRIC CROHN'S DISEASE (Weight: > 40kg (88 lbs)				☐ Inject 160mg SQ on Day 1 ar			
	· =	3 SYRINGE KIT	☐ Inject 80mg SQ on Day 1, Da		No refills		
	TIVE COLITIS (Weight: 20kg (44)			- Injust coming out on Day 1, De	19 2, and Bay 10		
	.4 mL (4) CITRATE FREE PEN	, , ,	4 PENS	☐ Inject 80mg SQ on Day 1, 40	mg on Day 8 and Day :	15 No refills	
•			Inject boing SQ on Day 1, 40	ing on Day 6 and Day	13		
☐ HUMIRA 40 mg/0.4 mL (4) CITRATE FREE SYRINGE PEDIATRIC ULCERATIVE COLITIS (Weight: ≥ 40kg (88lbs))				☐ Inject 160mg SQ on Day 1, 8	0mg on Day 8 and Day	15	
		4 PEN KIT			No refills		
				Inject boing SQ on Day 1, Da			
	NG THERAPY OPTIONS	CHOOSE ONE DI	RECTION FOI	R USE OR WRITE IN BELOW	QUANTITY	REFILLS	
	.4mL CITRATE FREE PEN		RY OTHER wee	ek □ 40 mg SQ EVERY week	84 Days Supply–	1	
	.4mL CITRATE FREE SYRINGE				Program Standard	1 year	
-	☐ HUMIRA 20 mg/0.2mL CITRATE FREE SYRINGE ☐ 20 mg SQ EVERY OTHER we				□Other:		
☐ HUMIRA 80 mg/0	.8mL CITRATE FREE PEN	□ 80 mg SQ EVEF	RY OTHER wee	ek			
HUMIRA:			Qty: Ref	fills:			
HUMIRA: Directions: Qty: Refills: Please contact myAbbVie Assist for questions about other available HUMIRA presentations							
PL	EASE SUBMIT PRESCRIPTION	S ACCORDING TO Y	OUR SPECIFI	C STATE LAWS, RULES AND R	EGULATIONS		
4 PRES	PRESCRIBER PLEASE SIGN AND DATE • PRESCRIBER MUST MANUALLY SIGN BELOW						
RUBBER STAMPS, SIGNATURE BY OTHER OFFICE PERSONNEL OR COMPUTER-GENERATED IMAGES ARE NOT ALLOWED							
PRESCRIBER SIGNATURE	<u> </u>		X		DATE:		
AND DATE:	☐ Substitution Permi		☐ Dispense	e as Written			
				Assist reserves the right to request add ion dispensed hereunder from any gover			
				e into the program should not influence t			

For full Prescribing Information please visit www.rxabbvie.com

form, I authorize the program and its representatives to transmit this prescription form electronically, by facsimile, or by mail to a pharmacy designated by the program for the dispensing of the medication called for herein. I understand that I may not delegate signature authority. I certify that treatment with this medication is medically necessary.



APPLICATION FOR HUMIRA® (adalimumab)

D-617927, AP5 NE; 1 N. WAUKEGAN RD NORTH CHICAGO, IL 60064

PHONE: 1-800-222-6885 FAX: 1-866-250-2803

5 PATIENT INFORMATION								
Patient Name:	DOB: Sex: M F							
SSN (last four digits ONLY): I I If you do not have an SSN, check here: □								
Mailing Address: City/State/Zip:								
Shipping Address (No P.O. Box):	City/State/Zip:							
Preferred Phone:	☐ Cellphone Alternate Phone: ☐ Work ☐ Hor	me						
Check the Box for								
Text Messages*	d medication reminders to the above number. Message and data rates may	у						
apply. I am not required to consent or provide my consent as a condition of receiving any goods of	or services. I can reply HELP for help. I can text STOP to unsubscribe any t	time.						
6 FINANCIAL AND MEDICAL INFORMATION								
Please include financial documentation for everyone in the household. A copy of your current federal tax return is preferred. If you do not file taxes, alternate documents are acceptable such as W-2 forms, Social Security Statements and Pay Stubs.								
Monthly \$ Number in Househol	d . Number in household . over 18 yrs old with income							
Household Income (including yourself)	over 18 yrs old with income							
Treating Physician Name:	Phone: Fax:							
If you have any changes to your medical information please call us at	1-800-222-6885							
7 INSURANCE INFORMATION I have no insurance covered to the second control of the secon	erage – go to Section 8							
INSURANCE TYPE:	Commercial Other:							
Please provide insurance details below and attach a front and back copy prescriptions such as a Pharmacy print-out and medical expenses for the								
MEDICAL INSURANCE	PRESCRIPTION INSURANCE							
Insurance Company:	Insurance Company:	Insurance Company:						
Insurance Co. Phone:	Insurance Co. Phone:							
Policy ID #: Group #:	Policy ID #: Group #:							
Policyholder Name: Relationship:	BIN #: PCN #:							
Do you have secondary insurance? Yes No Unsure								
Please provide your Medicare Part A Identification #: Value of your assets: \$								
	Assets include checking and savings accounts, CD's, stocks and bonds, savings bonds, mutual funds, IRAs and other investments, cash at home or anywhere							
else, and the value of your life insurance policies if turned in for cash right now. Do not								
8 ADDITIONAL PERMISSION FOR PURPOSES OF THE	,							
I permit myAbbVie Assist to speak with the following person about this application: Name: Relationship: Phone Number:								
DI EASE DEVIEW HIDAA ALITHODIZATION								
9 PATIENT CONSENT PLEASE REVIEW HIPAA AUTHORIZATION, PATIENT TERMS OF PARTICIPATION AND PRIVACY NOTICE IN SECTION 10 TO UNDERSTAND HOW WE USE YOUR PERSONAL INFORMATION								
I acknowledge that I have provided accurate and complete information and understand the Patient Terms of Participation in Section 10.								
CHECK THE BOX: I understand that I am providing written instructions to the Program under the Fair Credit Reporting Act authorizing the Program to obtain information about my credit profile from credit reporting agencies or other sources. I authorize the Program to obtain such information solely to determine PAP eligibility.								
My signature below certifies that I have read, understood and agree to the release of my protected health information pursuant to the HIPAA Authorization in Section 10.								
DATE: PATIENT SIGNATURE / LEGAL REPRESENTATIVE (inc	licate relationship) DATE	_						



10

APPLICATION FOR HUMIRA® (adalimumab)

D-617927, AP5 NE; 1 N. WAUKEGAN RD

NORTH CHICAGO, IL 60064

PHONE: 1-800-222-6885 FAX: 1-866-250-2803

HIPAA AUTHORIZATION, PATIENT TERMS OF PARTICIPATION AND PRIVACY NOTICE

HIPAA AUTHORIZATION Please provide signature in Section 9 of Enrollment Form

I authorize my healthcare providers, pharmacies, insurers, and laboratory testing facilities (my "Healthcare Companies") to disclose information about me, my medical condition, treatment, insurance coverage, and payment information in relation to my use of AbbVie products, to AbbVie to enroll me in and provide me with patient assistance and support for AbbVie products. I understand that information released under this Authorization will no longer be protected by HIPAA. I also understand that if my Healthcare Companies use or disclose my Personal Information for marketing purposes, they may receive financial remuneration. I understand that I am not required to sign this Authorization and that my Healthcare Companies will not condition my treatment, payment, enrollment, or eligibility for benefits on whether I sign this Authorization. However, I understand that if I do not sign this Authorization, I cannot take part in myAbbVie Assist (should I qualify). This Authorization will expire in 10 years or a shorter period if required by state law, unless I cancel it sooner by calling 1-800-222-6885 or by writing to myAbbVie Assist, D-617927, AP5 NE; 1 N. Waukegan Rd, North Chicago, IL 60064. I understand that cancelling my Authorization will not affect any use of my information that occurred before my request was processed.

PATIENT TERMS OF PARTICIPATION

myAbbVie Assist provides free medicine to qualifying patients. Participation in our program is free; we do not collect any fees from people seeking our assistance. Medication assistance is dependent on your ability to meet the eligibility criteria for program as determined by myAbbVie Assist. myAbbVie Assist does not have any obligation to provide the program services to you and is not liable in the provision of these services. The program may be changed or discontinued without notice. You will not seek reimbursement for any products dispensed under the program. You will notify the program if your insurance or financial situation changes. If this application has been completed by a personal representative, the personal representative will provide a copy of this completed application to you.

If you are a member of a Medicare plan including a Medicare Prescription Drug Plan and are qualified for program assistance, you will: (i) be eligible to obtain the medication from the program for a calendar year term (ii) not purchase this medication under your Medicare plan while enrolled in the program; (iii) not submit claims nor seek true out-of-pocket (TrOOP) credit for the medication provided during your enrollment; (iv) provide written notification to your Medicare Prescription Drug Plan, if applicable, that you are receiving your medication at no cost outside of the Medicare Part D benefit.

If you have questions, want to update your information, or terminate your enrollment, please call 1-800-222-6885 or write to us at D-617927, AP5 NE; 1 N. Waukegan Rd, North Chicago, IL 60064.

PATIENT PRIVACY NOTICE

myAbbVie Assist will use and disclose with authorized third parties your personal information including your financial and health information collected on this enrollment form and through participation in the program for the following purposes:

- (1) To determine your eligibility for the program and to provide you with related services, including transfer to a separate private or public payer program, reimbursement services, services to ship your medication, and other support services.
- (2) To obtain information from your credit profile about your income for the sole purpose of determining eligibility for the program. This notice serves as written instruction under the Fair Credit Reporting Act authorizing myAbbVie Assist to obtain this information.
- (3) To perform research and data analytics to develop and evaluate products, services, materials, and treatments.
- (4) To administer and maintain the quality of the program, including but not limited to case review, compliance checks, audit review and accounting purposes.

For additional information on how AbbVie processes your personal information, please visit www.abbvie.com/privacy.html.